TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment

TLC Stock Jumps on India's Approval of Liposomal Amphotericin B As Black Fungus Treatment
  • India's Central Drugs Standard Control Organization has approved Taiwan Liposome Company's TLC marketing application for Amphotericin B Liposome for 50mg Injection for immediate import to aid in the country's emergency of acute liposomal amphotericin B shortage.
  • AmphoTLC is a liposomal amphotericin B injection indicated for severe systemic fungal infections such as mucormycosis, a serious fungal infection known as a black fungus.
  • With a high number of COVID-19 infections in India, the number of COVID-19 associated mucormycosis (CAM) cases has also been rising.
  • Yesterday, TLC's subsidiary InspirMed Inc presented data on the potential advantages of inhalable liposome formulations that can be used as prophylaxis and treatment for COVID-19.
  • Price Action: TLC shares are up 27.6% at $6.24 during the premarket session on the last check Tuesday.

Posted In: BriefsIndiaBiotechNewsPenny StocksHealth CareFDAGeneral